VarmX raises funds to seek IND approval for VMX-C001
VMX-C001 is a modified recombinant human blood clotting factor X that enables patients taking direct oral anticoagulant blood thinners to undergo emergency surgery without the risk of bleeding.
eXmoor pharma has received an investment of around $35m in its Series A round to support the expansion of its cell and gene therapy production capability.
The products include Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Kimyrsa (oritavancin). Under the terms of the deal, Xediton Pharmaceuticals will handle the registration and commercialisation